Tanezumab: A In-depth Dive into the 880266-57-9 Immunoglobulin Product
Tanezumab, identified by the chemical designation 880266-57-9, represents a targeted antibody solution demonstrating significant promise in treating chronic osteoarthritis pain. This modified antibody selectively targets nerve growth protein, blocking its function and thereby reducing inflammation within affected joints . The ongoing data surrounding 880266-57-9 highlights its capacity to deliver noticeable pain alleviation while perhaps mitigating the need for traditional analgesics. Further research are currently underway to thoroughly determine its sustained safety and efficacy .
Grasping Tanezumab's Function in Discomfort Management: An Immune Protein View
Tanezumab, a unique treatment approach, offers Tanezumab antibody a specific pathway in chronic pain management. As a engineered antibody, it specifically targets and inhibits nerve growth factor (NGF), a critical molecule involved in neural pain signaling. Unlike conventional pain medications, tanezumab’s protein mechanism allows for a greater specific action, potentially decreasing the risk of some widespread side effects linked with generalized pain relief. However, its body's defense nature necessitates a careful evaluation of potential body's reactions and long-term impacts when employed within a complete pain therapy program.
Tanezumab Reagent (880266-57-9): Composition, Quality & Uses
The Tanezumab Reagent with the identifier 880266-57-9 is a essential component in various research applications, particularly concerning chronic inflammation treatment development. Achieving a high level of purity is paramount; therefore, rigorous analysis protocols are employed to guarantee its fitness for specific use. Our creation procedure focuses on ensuring refinement, employing sophisticated filtration techniques to remove impurities . Typical parameters include a >95% purity level as determined by Liquid Chromatography and comprehensive examination for molecular integrity. The key functions revolve around its role as a research tool for investigating the mechanisms of cartilage damage and innovative therapeutic interventions .
- Biomedical Investigations
- Therapeutic Development
- Pathway Studies
The Science Of Tanezumab:
Tanezumab, identified by the unique identifier 880266-57-9, represents a innovative biological protein targeting pain-sensing growth agent receptor (NGF). This mode of effect revolves about precisely attaching to NGF, thereby blocking its role and subsequent signal pathway. Scientists have demonstrated that this biological molecule provides opportunity for reducing persistent suffering, particularly in conditions like arthritic conditions and chronic back ache. More studies are underway to thoroughly characterize its effectiveness and security data.
New Progress in This Research: Focusing on the The Compound
Ongoing research surrounding tanezumab, a promising therapeutic compound, are increasingly focused on understanding the role of the specific reagent, 880266-57-9. The identification and precise evaluation of such molecular entity seems necessary for improving tanezumab's effectiveness and minimizing potential adverse outcomes. Early findings indicate that 880266-57-9 contributes a significant role in tanezumab’s mechanism of delivery. Further exploration will be required to entirely elucidate this reagent's impact.
Tanezumab Antibody (880266-57-9): Production, Characteristics, and Potential
The production process of tanezumab, an humanized monoclonal antibody (identified by CAS number 880266-57-9), typically involves mammalian cell culture, often utilizing Chinese hamster ovary cells for high yield. Its primary characteristic is its ability to selectively target and degrade cathepsin-K, an enzyme crucial for bone resorption. This binding mechanism results in a significant reduction in osteoclast activity. The molecule exhibits a defined molecular weight and specific amino acid sequence, allowing for detailed characterization through techniques such as mass spectrometry and protein sequencing. Consequently, tanezumab’s potential lies in treating conditions characterized by excessive bone loss, like osteoarthritis and metastatic bone disease, although clinical development has been complex due to adverse event profiles and ongoing evaluation.}